Holen Sie sich die Stockscreener-App
91.79
2.74%
2.45
Handel nachbörslich:
91.79
Schlusskurs vom Vortag:
$89.34
Offen:
$90.03
24-Stunden-Volumen:
984.68K
Relative Volume:
1.01
Marktkapitalisierung:
$5.26B
Einnahmen:
$360.35M
Nettoeinkommen (Verlust:
$-149.57M
KGV:
-31.01
EPS:
-2.96
Netto-Cashflow:
$-81.27M
1W Leistung:
+3.73%
1M Leistung:
-11.58%
6M Leistung:
-37.29%
1J Leistung:
-24.38%
1-Tages-Spanne:
$90.01
$92.69
1-Wochen-Bereich:
$84.37
$92.69
52-Wochen-Spanne:
$77.10
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Firmenname
Glaukos Corporation
Sektor
Branche
Telefon
949-367-9600
Adresse
1 GLAUKOS WAY, ALISO VIEJO, CA
Vergleichen Sie GKOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
91.79 | 5.12B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 1.41B | 577.90M | 6.95 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Eingeleitet | Truist | Buy |
| 2023-11-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-14 | Fortgesetzt | Stephens | Overweight |
| 2022-10-04 | Eingeleitet | Needham | Buy |
| 2022-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2022-02-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2021-11-03 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-12-09 | Eingeleitet | Oppenheimer | Perform |
| 2020-11-17 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Eingeleitet | Jefferies | Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Sell |
| 2020-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Hochstufung | Berenberg | Hold → Buy |
| 2019-12-12 | Herabstufung | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Eingeleitet | BTIG Research | Neutral |
| 2018-08-30 | Eingeleitet | Berenberg | Hold |
| 2018-08-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Bestätigt | Stifel | Hold |
| 2018-06-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-01 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-03-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Hochstufung | Stifel | Hold → Buy |
| 2016-10-27 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Glaukos Corporation Aktie (GKOS) Neueste Nachrichten
RSI + MACD Show Convergence for Glaukos Corporation2025 Growth vs Value & High Accuracy Trade Alerts - 선데이타임즈
Glaukos Announces Participation in Wells Fargo Healthcare Conference | GKOS Stock News - GuruFocus
Glaukos Announces Participation in Wells Fargo Healthcare Conference - sg.finance.yahoo.com
Glaukos Highlights Innovation in Recent Investor Presentation - TipRanks
What Glaukos (GKOS)'s Strong Q2 Results and Upgraded Guidance Mean For Shareholders - simplywall.st
Glaukos shares fall 41% after InvestingPro’s February overvaluation alert By Investing.com - Investing.com Nigeria
Glaukos (GKOS) Narrows Loss and Lifts Full-Year Outlook After Second-Quarter Results – What's Changed - simplywall.st
Glaukos Corporation (NYSE:GKOS) Q1 2025 Earnings Call Transcript - MSN
What catalysts could drive Glaukos Corporation stock higher in 2025Access high-quality stock research instantly - Jammu Links News
What is the dividend policy of Glaukos Corporation stockExceptional growth trajectory - Jammu Links News
How strong is Glaukos Corporation company’s balance sheetCapitalize on market momentum for big wins - Jammu Links News
What analysts say about Glaukos Corporation stockMaximize portfolio growth with expert advice - Jammu Links News
Is Glaukos Corporation a good long term investmentUnlock expert trading strategies for growth - Jammu Links News
What markets is MBIO expanding into Is Glaukos Corporation stock a good long term investment optionFree Trend-Following Techniques - Jammu Links News
Press Release: Glaukos Announces Second Quarter 2025 Financial Results - 富途牛牛
Glaukos Q2 Revenue Up 30%: Strong Adoption of Glaucoma Products in US and Global Expansion - AInvest
Glaukos (GKOS) Maintains Rating, Raises Price Target to $92. - AInvest
Glaukos Corporation's Q2 Earnings: Analysts Reassess Growth Prospects - AInvest
Glaukos Corporation (NYSE:GKOS) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo.co
Glaukos Corporation (NYSE:GKOS) Q2 2025 Earnings Call Transcript - Insider Monkey
Midday Stock Roundup: Envista Holdings up Nearly 10% - Orange County Business Journal
Glaukos (GKOS) Q2 Revenue Jumps 30% - Nasdaq
Glaukos Corp. Reports Record Growth Amid Challenges - TipRanks
Forecasting Glaukos Corporation price range with options dataOversold Recovery Opportunity Stocks Attract Buyers - metal.it
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised - Yahoo Finance
What is the risk reward ratio of investing in Glaukos Corporation stockSmart Portfolio Watchlist To Watch Now - Jammu Links News
Glaukos price target raised to $118 from $117 at BTIG - TipRanks
Mizuho lowers Glaukos stock price target to $130 on mixed outlook - Investing.com Nigeria
UBS Raises Price Target for Glaukos (GKOS) to $134, Keeps Buy Ra - GuruFocus
A Quick Look at Today's Ratings for Glaukos(GKOS.US), With a Forecast Between $115 to $130 - 富途牛牛
BTIG Adjusts Price Target for Glaukos (GKOS) Amid Sales Performance - GuruFocus
Glaukos (GKOS) Price Target Cut by Mizuho Amid Portfolio Concerns - GuruFocus
Glaukos price target lowered to $130 from $150 at Mizuho - TipRanks
Glaukos Corp's Q2 2025: Unraveling Key Contradictions in iDose Reimbursement, Reimplantation Timelines, and Growth Expectations - AInvest
Glaukos Corporation's 2025 Q2 Earnings: A Breakout Moment for MIGS and Dropless Innovation - AInvest
Glaukos Q2 2025 Earnings Call Transcript - MarketBeat
Glaukos Corporation Reports Strong Q2 2025 Growth - TipRanks
Glaukos Corp (GKOS): A High-Growth Play in Interventional Glaucoma Amid Regulatory and Market Headwinds - AInvest
Glaukos Corporation Revenue Projections and Strategic Insights - AInvest
Glaukos Announces Second Quarter 2025 Financial Results - BioSpace
Glaukos Corporation shares fall 2.49% after-hours after reporting a Q2 loss of $19.7 million. - AInvest
Earnings call transcript: Glaukos Corp beats Q2 2025 earnings estimates, stock dips - Investing.com
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Glaukos shares fall as revenue beat overshadowed by guidance concerns - Investing.com Nigeria
Glaukos Reports Record Q2 Sales, Raises 2025 Guidance - TipRanks
Glaukos Corp earnings beat by $0.02, revenue topped estimates - Investing.com Nigeria
Glaukos Q2 net sales up 30% YoY to $124.1mln. - AInvest
Short Term Charts Align With Long Term Uptrend in Glaukos CorporationSecure Capital Picks With Upside Potential Tracked - metal.it
Finanzdaten der Glaukos Corporation-Aktie (GKOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):